Enanta Pharmaceuticals 将来の成長

Future 基準チェック /16

Enanta Pharmaceuticalsは、23.9%と17.5%でそれぞれ年率23.9%で利益と収益が成長すると予測される一方、EPSはgrowで29.9%年率。

主要情報

23.9%

収益成長率

29.91%

EPS成長率

Biotechs 収益成長	24.7%
収益成長率	17.5%
将来の株主資本利益率	n/a
アナリストカバレッジ	Good
最終更新日	19 May 2026

今後の成長に関する最新情報

分析記事 • May 13

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Just Released Its Second-Quarter Earnings: Here's What Analysts Think

The quarterly results for Enanta Pharmaceuticals, Inc. ( NASDAQ:ENTA ) were released last week, making it a good time...

分析記事 • Feb 12

Analysts Are Updating Their Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Estimates After Its First-Quarter Results

Enanta Pharmaceuticals, Inc. ( NASDAQ:ENTA ) investors will be delighted, with the company turning in some strong...

Recent updates

分析記事 • May 13

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Just Released Its Second-Quarter Earnings: Here's What Analysts Think

The quarterly results for Enanta Pharmaceuticals, Inc. ( NASDAQ:ENTA ) were released last week, making it a good time...

分析記事 • Feb 12

Analysts Are Updating Their Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Estimates After Its First-Quarter Results

Enanta Pharmaceuticals, Inc. ( NASDAQ:ENTA ) investors will be delighted, with the company turning in some strong...

分析記事 • Dec 20

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Stock Catapults 27% Though Its Price And Business Still Lag The Industry

Despite an already strong run, Enanta Pharmaceuticals, Inc. ( NASDAQ:ENTA ) shares have been powering on, with a gain...

分析記事 • Nov 26

Health Check: How Prudently Does Enanta Pharmaceuticals (NASDAQ:ENTA) Use Debt?

The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...

分析記事 • Oct 30

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Not Doing Enough For Some Investors As Its Shares Slump 30%

The Enanta Pharmaceuticals, Inc. ( NASDAQ:ENTA ) share price has softened a substantial 30% over the previous 30 days...

Seeking Alpha • Sep 29

Enanta: Despite Primary Endpoint Miss Zelicapavir Could Benefit From Trial Design Change

Summary Enanta Pharmaceuticals remains a Buy as zelicapavir shows multiple positive efficacy endpoints in RSV despite missing its primary endpoint in the phase 2b study. Zelicapavir demonstrated statistically significant improvements in PGI-S scores and viral load reduction, supporting potential for phase 3 advancement pending FDA feedback. Strong cash position funds operations into 2028, with ongoing MAVYRET/MAVIRET royalties and a manageable quarterly cash burn. Upcoming catalysts include an end-of-phase 2 FDA meeting for zelicapavir and continued pipeline expansion with STAT6 and KIT inhibitor programs. Read the full article on Seeking Alpha

分析記事 • Sep 03

Enanta Pharmaceuticals, Inc.'s (NASDAQ:ENTA) Price Is Right But Growth Is Lacking After Shares Rocket 27%

The Enanta Pharmaceuticals, Inc. ( NASDAQ:ENTA ) share price has done very well over the last month, posting an...

分析記事 • Aug 14

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Third-Quarter Results: Here's What Analysts Are Forecasting For Next Year

Enanta Pharmaceuticals, Inc. ( NASDAQ:ENTA ) just released its latest quarterly results and things are looking bullish...

分析記事 • May 18

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Second-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For This Year

Investors in Enanta Pharmaceuticals, Inc. ( NASDAQ:ENTA ) had a good week, as its shares rose 9.1% to close at US$5.75...

分析記事 • Mar 31

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Not Doing Enough For Some Investors As Its Shares Slump 27%

Enanta Pharmaceuticals, Inc. ( NASDAQ:ENTA ) shareholders won't be pleased to see that the share price has had a very...

分析記事 • Feb 14

Enanta Pharmaceuticals, Inc.'s (NASDAQ:ENTA) Shares Bounce 55% But Its Business Still Trails The Industry

Enanta Pharmaceuticals, Inc. ( NASDAQ:ENTA ) shareholders are no doubt pleased to see that the share price has bounced...

分析記事 • Nov 30

Analysts Have Been Trimming Their Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Price Target After Its Latest Report

The analysts might have been a bit too bullish on Enanta Pharmaceuticals, Inc. ( NASDAQ:ENTA ), given that the company...

分析記事 • Nov 27

Benign Growth For Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Underpins Stock's 27% Plummet

To the annoyance of some shareholders, Enanta Pharmaceuticals, Inc. ( NASDAQ:ENTA ) shares are down a considerable 27...

分析記事 • Oct 05

Health Check: How Prudently Does Enanta Pharmaceuticals (NASDAQ:ENTA) Use Debt?

The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...

分析記事 • Aug 08

Here's What Analysts Are Forecasting For Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) After Its Third-Quarter Results

A week ago, Enanta Pharmaceuticals, Inc. ( NASDAQ:ENTA ) came out with a strong set of third-quarter numbers that could...

分析記事 • Jul 24

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Held Back By Insufficient Growth Even After Shares Climb 26%

Enanta Pharmaceuticals, Inc. ( NASDAQ:ENTA ) shares have had a really impressive month, gaining 26% after a shaky...

分析記事 • Jun 19

Is Enanta Pharmaceuticals (NASDAQ:ENTA) Using Debt In A Risky Way?

The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...

分析記事 • May 09

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Just Released Its Second-Quarter Earnings: Here's What Analysts Think

Shareholders might have noticed that Enanta Pharmaceuticals, Inc. ( NASDAQ:ENTA ) filed its quarterly result this time...

分析記事 • Mar 05

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Shares Fly 27% But Investors Aren't Buying For Growth

Despite an already strong run, Enanta Pharmaceuticals, Inc. ( NASDAQ:ENTA ) shares have been powering on, with a gain...

分析記事 • Feb 12

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

Enanta Pharmaceuticals, Inc. ( NASDAQ:ENTA ) just released its latest quarterly report and things are not looking...

分析記事 • Aug 13

Time To Worry? Analysts Are Downgrading Their Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Outlook

The latest analyst coverage could presage a bad day for Enanta Pharmaceuticals, Inc. ( NASDAQ:ENTA ), with the analysts...

業績と収益の成長予測

NasdaqGS:ENTA - アナリストの将来予測と過去の財務データ ( )USD Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
9/30/2028	76	-62	1	-66	4
9/30/2027	68	-57	-50	-34	6
9/30/2026	69	-54	-42	29	4
3/31/2026	69	-62	-10	-8	N/A
12/31/2025	67	-72	-18	-14	N/A
9/30/2025	65	-82	-32	-19	N/A
6/30/2025	65	-92	-44	-23	N/A
3/31/2025	64	-96	-82	-55	N/A
12/31/2024	67	-105	-96	-71	N/A
9/30/2024	68	-116	-97	-79	N/A
6/30/2024	72	-115	-100	-90	N/A
3/31/2024	73	-132	-113	-107	N/A
12/31/2023	74	-138	-99	-93	N/A
9/30/2023	79	-134	-112	-103	N/A
6/30/2023	81	-132	-106	-97	N/A
3/31/2023	81	-125	-102	-95	N/A
12/31/2022	82	-121	-112	-107	N/A
9/30/2022	86	-122	-87	-85	N/A
6/30/2022	89	-120	-91	-90	N/A
3/31/2022	92	-112	-91	-90	N/A
12/31/2021	93	-101	-69	-68	N/A
9/30/2021	97	-79	-71	-70	N/A
6/30/2021	97	-84	-65	-64	N/A
3/31/2021	94	-74	-40	-39	N/A
12/31/2020	102	-58	-21	-20	N/A
9/30/2020	122	-36	6	7	N/A
6/30/2020	150	2	30	31	N/A
3/31/2020	176	24	35	38	N/A
12/31/2019	188	34	N/A	54	N/A
9/30/2019	205	46	N/A	71	N/A
6/30/2019	221	65	N/A	91	N/A
3/31/2019	234	78	N/A	93	N/A
12/31/2018	238	86	N/A	55	N/A
9/30/2018	207	72	N/A	29	N/A
6/30/2018	215	81	N/A	58	N/A
3/31/2018	166	52	N/A	49	N/A
12/31/2017	131	34	N/A	54	N/A
9/30/2017	103	18	N/A	53	N/A
6/30/2017	40	-21	N/A	-7	N/A
3/31/2017	46	-13	N/A	-4	N/A
12/31/2016	50	-10	N/A	9	N/A
9/30/2016	88	22	N/A	36	N/A
6/30/2016	90	29	N/A	36	N/A
3/31/2016	87	33	N/A	23	N/A
12/31/2015	132	63	N/A	112	N/A
9/30/2015	161	79	N/A	77	N/A
6/30/2015	149	68	N/A	74	N/A

アナリストによる今後の成長予測

収入対貯蓄率: ENTA今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: ENTA今後 3 年間、利益が出ない状態が続くと予測されています。

高成長収益: ENTA今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: ENTAの収益 ( 17.5% ) US市場 ( 11.9% ) よりも速いペースで成長すると予測されています。

高い収益成長: ENTAの収益 ( 17.5% ) 20%よりも低い成長が予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: ENTAの自己資本利益率が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です

成長企業の発掘

企業分析と財務データの現状

データ	最終更新日（UTC時間）
企業分析	2026/06/09 13:07
終値	2026/06/09 00:00
収益	2026/03/31
年間収益	2025/09/30

データソース

企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。

パッケージ	データ	タイムフレーム	米国ソース例
会社財務	10年	損益計算書キャッシュ・フロー計算書貸借対照表	SECフォーム10-K SECフォーム10-Q
アナリストのコンセンサス予想	+プラス3年	予想財務アナリストの目標株価	アナリストリサーチレポート Blue Matrix
市場価格	30年	株価配当、分割、措置	ICEマーケットデータ SECフォームS-1
所有権	10年	トップ株主インサイダー取引	SECフォーム4 SECフォーム13D
マネジメント	10年	リーダーシップ・チーム取締役会	SECフォーム10-K SECフォームDEF 14A
主な進展	10年	会社からのお知らせ	SECフォーム8-K

* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用^。

特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。

分析モデルとスノーフレーク

本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。

シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。

業界およびセクターの指標

私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。

アナリスト筋

Enanta Pharmaceuticals, Inc. 6 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、。アナリストの投稿は一日中更新されます。19

アナリスト	機関
Brian Skorney	Baird
Geoffrey Meacham	Barclays
Patrick Trucchio	Berenberg

Enanta Pharmaceuticals 将来の成長

Future 基準チェック /16

主要情報

今後の成長に関する最新情報

Consensus estimates of losses per share improve by 19%

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Just Released Its Second-Quarter Earnings: Here's What Analysts Think

Price target decreased by 8.6% to US$18.50

Price target increased by 7.2% to US$20.50

Analysts Are Updating Their Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Estimates After Its First-Quarter Results

Consensus EPS estimates fall by 33%

Recent updates

Consensus estimates of losses per share improve by 19%

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Just Released Its Second-Quarter Earnings: Here's What Analysts Think

Enanta Pharmaceuticals, Inc. to Report Q3, 2026 Results on Aug 10, 2026

Second quarter 2026 earnings: EPS exceeds analyst expectations

Enanta Pharmaceuticals Inc Announces First Participant Dosed in Phase 1 Clinical Trial of Edp-978

Price target decreased by 8.6% to US$18.50

Price target increased by 7.2% to US$20.50

Analysts Are Updating Their Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Estimates After Its First-Quarter Results

First quarter 2026 earnings: EPS and revenues exceed analyst expectations

Enanta Pharmaceuticals, Inc. to Report Q2, 2026 Results on May 11, 2026

Enanta Pharmaceuticals, Inc., Annual General Meeting, Mar 11, 2026

Enanta Pharmaceuticals, Inc. Provides Update on Its Research and Development Programs

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Stock Catapults 27% Though Its Price And Business Still Lag The Industry

Consensus EPS estimates fall by 33%

President recently sold US$67k worth of stock

President notifies of intention to sell stock

Health Check: How Prudently Does Enanta Pharmaceuticals (NASDAQ:ENTA) Use Debt?

Consensus EPS estimates upgraded to US$2.30 loss

Full year 2025 earnings: EPS and revenues miss analyst expectations

Enanta Pharmaceuticals, Inc. to Report Q1, 2026 Results on Feb 09, 2026

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Not Doing Enough For Some Investors As Its Shares Slump 30%

Enanta Pharmaceuticals, Inc. Presents New Data for Zelicapavir, its N-Protein Inhibitor and EDP-323, L-Protein Inhibitor

New major risk - Shareholder dilution

Price target increased by 9.8% to US$19.14

Enanta Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $65 million.

Enanta Pharmaceuticals Reports Positive Topline Results from Its Phase 2B Study of Zelicapavir for the Treatment of Respiratory Syncytial Virus in High-Risk Adults

New major risk - Share price stability

Enanta: Despite Primary Endpoint Miss Zelicapavir Could Benefit From Trial Design Change

Enanta Pharmaceuticals, Inc. Announces Demise of Paul J. Mellett Jr, Chief Financial and Administrative Officer

Enanta Pharmaceuticals, Inc.'s (NASDAQ:ENTA) Price Is Right But Growth Is Lacking After Shares Rocket 27%

Enanta Pharmaceuticals, Inc. Announces Executive Changes on August 26, 2025

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Third-Quarter Results: Here's What Analysts Are Forecasting For Next Year

Third quarter 2025 earnings: EPS and revenues exceed analyst expectations

Enanta Pharmaceuticals, Inc. to Report Q4, 2025 Results on Nov 17, 2025

New major risk - Revenue and earnings growth

Enanta Pharmaceuticals, Inc. Announces U.S. Food and Drug Administration Approves Label Expansion for MAVYRET (Glecaprevir/Pibrentasvir), Oral Pangenotypic Direct Acting Antiviral (DAA) Therapy

Consensus EPS estimates upgraded to US$3.73 loss, revenue downgraded

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Second-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For This Year

Price target increased by 12% to US$17.00

Second quarter 2025 earnings: EPS exceeds analyst expectations while revenues lag behind

Enanta Pharmaceuticals, Inc. to Report Q3, 2025 Results on Aug 11, 2025

New minor risk - Market cap size

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Not Doing Enough For Some Investors As Its Shares Slump 27%

President recently bought US$256k worth of stock

Enanta Pharmaceuticals, Inc.'s (NASDAQ:ENTA) Shares Bounce 55% But Its Business Still Trails The Industry

New minor risk - Share price stability

Price target decreased by 8.6% to US$15.43

First quarter 2025 earnings: EPS exceeds analyst expectations while revenues lag behind

Enanta Pharmaceuticals, Inc. to Report Q2, 2025 Results on May 12, 2025

Enanta Pharmaceuticals, Inc., Annual General Meeting, Mar 13, 2025

New major risk - Revenue and earnings growth

Price target decreased by 13% to US$15.75

Enanta Pharmaceuticals Announces Positive Topline Results from First-In-Pediatrics Phase 2 Study Evaluating Zelicapavir for the Treatment of Respiratory Syncytial Virus

Analysts Have Been Trimming Their Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Price Target After Its Latest Report

Price target decreased by 7.6% to US$18.13

Benign Growth For Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Underpins Stock's 27% Plummet

Full year 2024 earnings: EPS and revenues miss analyst expectations

Health Check: How Prudently Does Enanta Pharmaceuticals (NASDAQ:ENTA) Use Debt?

New major risk - Revenue and earnings growth

Here's What Analysts Are Forecasting For Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) After Its Third-Quarter Results

New major risk - Revenue and earnings growth

Third quarter 2024 earnings: EPS and revenues exceed analyst expectations

Enanta Pharmaceuticals, Inc. to Report Q4, 2024 Results on Nov 25, 2024

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Held Back By Insufficient Growth Even After Shares Climb 26%

Senior VP & Chief Medical Officer notifies of intention to sell stock

Is Enanta Pharmaceuticals (NASDAQ:ENTA) Using Debt In A Risky Way?

Insider notifies of intention to sell stock

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Just Released Its Second-Quarter Earnings: Here's What Analysts Think

Enanta Pharmaceuticals, Inc. to Report Q3, 2024 Results on Aug 05, 2024